LLY

Executive Summary

Eli Lilly and Company is a prominent pharmaceutical firm characterized by robust growth, primarily propelled by its leading cardiometabolic health products, including the GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity. The company demonstrated significant financial performance in Q1 2026 with a 56% increase in revenue to $19.8 billion, leading to an upward revision of its full-year 2026 revenue guidance to between $82.0 billion and $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00. Recent regulatory approvals, such as the U.S. FDA clearance of Foundayo (orforglipron) as an oral GLP-1, further solidifies its market position. Eli Lilly is strategically investing in expanding its manufacturing capabilities to meet the high demand for its innovative medicines and maintain a competitive edge in the market.

Technical Outlook

Eli Lilly's technical outlook as of early September 2026 presents a mixed short-term picture within a medium-term rising trend channel. The Relative Strength Index (RSI) ranges from 35 to 43, indicating neutral to potentially oversold conditions, with some technical indicators suggesting a 'Sell' signal. The Moving Average Convergence Divergence (MACD) line is currently below its signal line, signaling bearish momentum. Most short-term moving averages (5-day, 10-day, 20-day, 50-day) are in 'Sell' territory as the stock trades below these levels. However, longer-term indicators like the 100-day and 200-day exponential moving averages suggest a 'Buy' as the price remains above them. In the medium term, the stock maintains a rising trend channel, reflecting sustained investor interest, with identified support around $1100.

Fundamental Health

Eli Lilly demonstrates robust fundamental health, underpinned by impressive financial growth and a strong product portfolio. In 2025, the company reported revenues of $65.18 billion, marking a 44.70% increase year-over-year, and earnings of $20.64 billion, up 94.90%. Q1 2026 saw a substantial 56% revenue surge to $19.8 billion, prompting the company to raise its full-year 2026 revenue guidance to between $82.0 billion and $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00. With a market capitalization exceeding $1 trillion, Eli Lilly is a pharmaceutical giant. The company's P/E ratio, around 39.06 or 37.75, reflects a premium valuation driven by high growth expectations, particularly from its GLP-1 drug franchise. The dividend yield currently stands at approximately 0.58%.

Key Catalysts

• Continued market expansion and adoption of Foundayo (orforglipron), especially its oral formulation, following its U.S. FDA approval in 2026.
• Positive clinical data readouts for retatrutide, a triple-agonist, across its various indications including type 2 diabetes and obesity.
• Performance in Q2 2026 and subsequent earnings reports, along with updated financial guidance, will influence investor sentiment.
• Outcomes from competitor clinical trials (e.g., Amgen's MariTide, Roche's CT-388) and presentations at scientific conferences, which could alter the competitive landscape in the GLP-1 market.
• Further strategic acquisitions or advancements in its diverse pipeline, particularly in areas like Alzheimer's, cancer, and immunology.